Dong-A Pharmaceutical (President and CEO Won-Bae Kim) signed export contracts for Zydena® with a
total of 19 countries including Thailand, the Commonwealth of Independent States (CIS) and the Middle East &
North Africa (MENA) worth USD 58 million.




The company notified that it signed three deals for Zydena® (for five years) – worth USD 15 million with
B.L.HUA of Thailand, USD 20 million sales contracts with Techestvennye JSC of Russia and the 10 CIS
countries, and USD 23 million sales contracts with Hikma of Jordan, the biggest pharmaceutical firm in the
Middle East, and others in the Middle East & North Africa (MENA).




This would render Zydena®, the erectile dysfunction treatment developed for the fourth time in the world, to
be exported to the Middles, GCC and Russia, a total of 28 countries, and its accumulated export contract
volume would reach USD 138 million (for five years), the biggest as a domestic new drug.




Dong-A Pharmaceutical has actively advanced into highly competitive regions to maximize added values from
exporting new drugs. Its overseas advancement has been accelerated especially in Southeast Asia, Latin
America and the Middle East. The company will continue to expand exporting its new drugs and high value
brand name pharmaceuticals with a basis in the three regions.




CEO Kim, Won-Bae of Dong-A Pharmaceutical said regarding good responses on Zydena® in the global
market, “Its strong safety and efficacy in the FDA’s Phase II clinical trial has been proven, and its stronger
excellence in duration and side effects has been highly claimed by overseas pharmaceutical players.” He
predicted, “Once Zydena® is released in the U.S. and Europe after being approved by the FDA, not only its
safety and efficacy but also cost advantages would further enhance its success potentials in the global
market.”




Moreover, he said, “The overseas market is hinting at a new possibility to us,” adding, “In order for Dong-A
Pharmaceutical to become one of the multinational players as a global player let alone the No.1 player in the
domestic market, we will strive to develop new drugs, foster mega-scale items and carve out a new market
abroad.”




Overseas Sales Division Director Chang, Gi-ho at Dong-A Pharmaceutical confidently said, “In our export
contract with Hikma of the Middle East, it said it would pay the milestones upon signing the contract,
recognizing Zydena®'s excellence and product quality as a new drug. It would be the No.1 product in the
erectile dysfunction treatment market in the Middle East in partnership with local partners.” He added,
“Currently, we are negotiating on signing an export contract with pharmaceutical companies in Southeast Asia
including Malaysia, Singapore, the Philippines, Indonesia and Taiwan. We are also seeking to expand our
overseas advancement into East Europe with negotiations underway with companies in the Federal Republic of
Yugoslavia in the Balkans.”




The current domestic pharmaceutical market is exposing limits due to the Korea-US FTA, positive systems,
lower drug prices and other changes in the overall environment. The pharmaceutical industry requires new
growth engines to domestic players, favorably assessing that Dong-A Pharmaceutical is achieving high
records in new drug development and overseas export, and is guiding new directions for domestic players.






# # #




About Dong-A Pharmaceutical

Dong-A is Korea’s leading pharmaceutical company. Based on its corporate philosophy that the greatest value
is life, Dong-A strives to be a responsible corporate citizen that contributes to the health and welfare of
humankind. Over the past 42 years, Dong-A has maintained a re